These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22693732)

  • 1. [Basal subtype of breast cancer--a unit of specific characteristics of immunophenotyping?].
    Niemiec J; Ryś J
    Pol J Pathol; 2011 Dec; 62(4 Suppl 4):s36-44. PubMed ID: 22693732
    [No Abstract]   [Full Text] [Related]  

  • 2. Triple-negative breast cancer: what the radiologist needs to know.
    Whitman GJ; Albarracin CT; Gonzalez-Angulo AM
    Semin Roentgenol; 2011 Jan; 46(1):26-39. PubMed ID: 21134526
    [No Abstract]   [Full Text] [Related]  

  • 3. What is triple-negative breast cancer?
    Irvin WJ; Carey LA
    Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.
    Tang P; Wang J; Hicks DG; Wang X; Schiffhauer L; McMahon L; Yang Q; Shayne M; Huston A; Skinner KA; Griggs J; Lyman G
    Cancer Invest; 2010 Nov; 28(9):978-82. PubMed ID: 20690804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Endocrinology of breast cancer as a heterogeneous disease: a decade after the millennium].
    Bershteĭn LM
    Vopr Onkol; 2013; 59(3):292-8. PubMed ID: 23909028
    [No Abstract]   [Full Text] [Related]  

  • 7. [Gene expression analysis and its clinical use in breast tumors].
    Semiglazov VF; Semiglazov VV; Moiseenko FV; Bogdanov AA; Boĭtsov VV; Viaz'min SV; Gorab DN; Chubenko VA; Brezhnev NV; Luk'ianchikova VS; Dubina MV
    Vopr Onkol; 2013; 59(1):25-9. PubMed ID: 23805447
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
    Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with bone metastasis in breast cancer: a preliminary study in an Indonesian population.
    Irawan C; Hukom R; Prayogo N
    Acta Med Indones; 2008 Oct; 40(4):178-80. PubMed ID: 19153424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
    Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
    Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-negative breast cancers and the human mammary epithelial cell hierarchy.
    Ganesan S; Karantza V; Oza J; Toppmeyer D
    Breast Dis; 2010; 32(1-2):49-61. PubMed ID: 22045329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor-based predictors of response in breast cancer.
    McGovern UB; Stebbing J
    Future Oncol; 2009 Apr; 5(3):283-6. PubMed ID: 19374534
    [No Abstract]   [Full Text] [Related]  

  • 13. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features.
    Geradts J; Bean SM; Bentley RC; Barry WT
    Cancer Invest; 2010 Nov; 28(9):969-77. PubMed ID: 20873988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-negative breast cancers: unique clinical presentations and outcomes.
    Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
    Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative breast cancer and brain metastases.
    Sait B; Cinar E; Altundag K
    Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):84. PubMed ID: 19751969
    [No Abstract]   [Full Text] [Related]  

  • 17. Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related.
    Neven P; Pochet N; Drijkoningen M; Amant F; De Smet F; Paridaens R; Christiaens MR; Vergote I
    J Clin Oncol; 2006 Jun; 24(16):2595; author reply 2595-7. PubMed ID: 16735717
    [No Abstract]   [Full Text] [Related]  

  • 18. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative breast cancer.
    Oncology (Williston Park); 2010 Oct; 24(10 Suppl):40a. PubMed ID: 21275325
    [No Abstract]   [Full Text] [Related]  

  • 20. HER-2 protein overexpressing breast cancer without gene amplification shows higher hormone receptor expression than HER-2 protein overexpressing breast cancer with gene amplification.
    Koo JS; Jung W; Yang WI
    Int J Surg Pathol; 2011 Aug; 19(4):425-32. PubMed ID: 19666946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.